Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Phosphoinositide 3-kinase δ (PI3Kδ) has a key role in lymphocytes, and inhibitors that target this PI3K have been approved for treatment of B cell malignancies 1–3 . Although studies in mouse models of solid tumours have demonstrated that PI3Kδ inhibitors (PI3Kδi) can induce anti-tumour immunity 4,5 , its effect on solid tumours in humans remains unclear. Here we assessed the effects of the PI3Kδi AMG319 in human patients with head and neck cancer in a neoadjuvant, double-blind, placebo-controlled randomized phase II trial (EudraCT no. 2014-004388-20). PI3Kδ inhibition decreased the number of tumour-infiltrating regulatory T (T reg ) cells and enhanced the cytotoxic potential of tumour-infiltrating T cells. At the tested doses of AMG319, immune-related adverse events (irAEs) required treatment to be discontinued in 12 out of 21 of patients treated with AMG319, suggestive of systemic effects on T reg cells. Accordingly, in mouse models, PI3Kδi decreased the number of T reg cells systemically and caused colitis. Single-cell RNA-sequencing analysis revealed a PI3Kδi-driven loss of tissue-resident colonic ST2 T reg cells, accompanied by expansion of pathogenic T helper 17 (T H 17) and type 17 CD8 + T (T C 17) cells, which probably contributed to toxicity; this points towards a specific mode of action for the emergence of irAEs. A modified treatment regimen with intermittent dosing of PI3Kδi in mouse models led to a significant decrease in tumour growth without inducing pathogenic T cells in colonic tissue, indicating that alternative dosing regimens might limit toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
La Manno, G., Soldatov, R., Zeisel, A., Braun, E., Hochgerner, H., Petukhov, V., Lidschreiber, K., Kastriti, M. E., Lönnerberg, P., Furlan, A., et al. (2018) · Nature · doi:10.1038/s41586-018-0414-6 · Cited by 4,118
Finak, G., McDavid, A., Yajima, M., Deng, J., Gersuk, V., Shalek, A. K., Slichter, C. K., Miller, H. W., McElrath, M. J., Prlic, M., et al. (2015) · Genome Biology · doi:10.1186/s13059-015-0844-5 · Cited by 3,159
Generalizing RNA velocity to transient cell states through dynamical modeling
Bergen, V., Lange, M., Peidli, S., Wolf, F. A., & Theis, F. J. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0591-3 · Cited by 2,951 · cited 1×
“Notably, RNA velocity analysis, a tool to assess the developmental stage of cells in scRNA-seq data 23,24 , infers a developmental trajectory over several progenitor states (cluster 2,4 and then 0) culminating in clonally expanded ST2 T reg cells (cluster 8) in placebo-treated mice (Fig.”
MethodTOX transcriptionally and epigenetically programs CD8+ T cell exhaustion
Khan, O., Giles, J. R., McDonald, S., Manne, S., Ngiow, S. F., Patel, K. P., Werner, M. T., Huang, A. C., Alexander, K. A., Wu, J. E., et al. (2019) · Nature · doi:10.1038/s41586-019-1325-x · Cited by 1,646
TOX is a critical regulator of tumour-specific T cell differentiation
Scott, A. C., Dündar, F., Zumbo, P., Chandran, S. S., Klebanoff, C. A., Shakiba, M., Trivedi, P., Menocal, L., Appleby, H., Camara, S., et al. (2019) · Nature · doi:10.1038/s41586-019-1324-y · Cited by 1,106
CD4 + Regulatory T Cells Control T H 17 Responses in a Stat3-Dependent Manner
Chaudhry, A., Rudra, D., Treuting, P., Samstein, R. M., Liang, Y., Kas, A., & Rudensky, A. Y. (2009) · Science · doi:10.1126/science.1172702 · Cited by 1,000
A Distinct Function of Regulatory T Cells in Tissue Protection
Arpaia, N., Green, J. A., Moltedo, B., Arvey, A., Hemmers, S., Yuan, S., Treuting, P. M., & Rudensky, A. Y. (2015) · Cell · doi:10.1016/j.cell.2015.08.021 · Cited by 991
Hu, X., & Ivashkiv, L. B. (2009) · Immunity · doi:10.1016/j.immuni.2009.09.002 · Cited by 928 · cited 1×
“5c) and higher expression of several interferon-related response genes 21,22 ( Stat1 , Stat3 and Ifrd1 ), suggestive of a pro-inflammatory environment (Extended Data Fig.”
BackgroundSingle-Cell Transcriptomics of Regulatory T Cells Reveals Trajectories of Tissue Adaptation
Miragaia, R. J., Gomes, T., Chomka, A., Jardine, L., Riedel, A., Hegazy, A. N., Whibley, N., Tucci, A., Chen, X., Lindeman, I., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.01.001 · Cited by 499 · cited 1×
“4a, b), in agreement with previous studies 13,14 .”
ResultTh17 cells give rise to Th1 cells that are required for the pathogenesis of colitis
Harbour, S. N., Maynard, C. L., Zindl, C. L., Schoeb, T. R., & Weaver, C. T. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1415675112 · Cited by 427
Cited by
PI3K inhibitors are finally coming of age
Vanhaesebroeck, B., Perry, M. W. D., Brown, J. R., André, F., & Okkenhaug, K. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00209-1 · Cited by 476
Self-citationBeyond PI3Ks: targeting phosphoinositide kinases in disease
Burke, J. E., Triscott, J., Emerling, B. M., & Hammond, G. R. V. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00582-5 · Cited by 156
Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review
Li, Y., Zhang, C., Jiang, A., Lin, A., Liu, Z., Cheng, X., Wang, W., Cheng, Q., Zhang, J., Wei, T., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05104-y · Cited by 105
“This points to a specific mode of action for the emergence of immune-related adverse events (IRAEs) [150].”
BackgroundSelf-citationThibault, B., Ramos-Delgado, F., & Guillermet-Guibert, J. (2023) · Cancers · doi:10.3390/cancers15030784 · Cited by 40
Metadata
- Authors
- Eschweiler, S., Ramírez-Suástegui, C., Li, Y., King, E., Chudley, L., Thomas, J., Wood, O., von Witzleben, A., Jeffrey, D., McCann, K., Simon, H., Mondal, M., Wang, A., Dicker, M., Lopez-Guadamillas, E., Chou, T.-F., Dobbs, N. A., Essame, L., Acton, G., Kelly, F., Halbert, G., Sacco, J. J., Schache, A. G., Shaw, R., McCaul, J. A., Paterson, C., Davies, J. H., Brennan, P. A., Singh, R. P., Loadman, P. M., Wilson, W., Hackshaw, A., Seumois, G., Okkenhaug, K., Thomas, G. J., Jones, T. M., Ay, F., Friberg, G., Kronenberg, M., Vanhaesebroeck, B., Vijayanand, P., & Ottensmeier, C. H.
- Venue
- Nature
- Published
- 2022-05-04
- Volume
- 605
- Issue
- 7911
- Pages
- 741-746
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W4229001659
- Cited by
- 99
- References
- 15
- FWCI
- 6.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs. https://app.cochat.ai/papers/10.1038/s41586-022-04685-2
- The paper
- Eschweiler, S., Ramírez-Suástegui, C., Li, Y., King, E., Chudley, L., Thomas, J., Wood, O., von Witzleben, A., Jeffrey, D., McCann, K., Simon, H., Mondal, M., Wang, A., Dicker, M., Lopez-Guadamillas, E., Chou, T.-F., Dobbs, N. A., Essame, L., Acton, G., . . . Ottensmeier, C. H. (2022). Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs. Nature. https://doi.org/10.1038/s41586-022-04685-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.